Arlene A Forastiere, M.D.

Headshot of Arlene A Forastiere
  • Professor of Oncology


Head and Neck Cancers, Medical Oncology

Research Interests

Head and neck cancer, esophageal cancer

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-955-8964
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
The Johns Hopkins Hospital (Main Entrance) - Google Maps

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Google Maps



  • Professor of Oncology
  • Professor of Otolaryngology - Head and Neck Surgery
  • Professor of Radiation Oncology and Molecular Radiation Sciences

Departments / Divisions



  • MD; New York Medical College (1975)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (1978)
  • American Board of Internal Medicine (Medical Oncology) (1981)

Research & Publications

Selected Publications

Forastiere, A.A.; Trotti, A.; Pfister, D.G.; Grandis, J.R. Head and neck cancer: recent advances and new standards of care. J Clin Oncol. 2006 Jun 10;24(17):2603-2605.
Gibson, M.K.; Forastiere, A.A. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol. 2006 Jul;7(7):565-574.
Gilbert, J.; Li, Y.; Pinto, H.A.; Jennings, T.; Kies, M.S.; Silverman, P.; Forastiere, A.A. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006 Mar;28(3):197-204.
Heath, E.I.; Burtness, B.A.; Kleinberg, L.; Salem, R.R.; Yang, S.C.; Heitmiller, R.F.; Canto, M.I.; Knisely, J.P.; Topazian, M.; Montgomery, E.; Tsottles, N.; Pithavala, Y.; Rohmiller, B.; Collier, M.; Forastiere, A.A. Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Invest New Drugs. 2006 Mar;24(2):135-140.
Jimeno, A.; Kulesza, P.; Kincaid, E.; Bouaroud, N.; Chan, A.; Forastiere, A.; Brahmer, J.; Clark, D.P.; Hidalgo, M. C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res. 2006 Feb 15;66(4):2385-2390.
Kleinberg, L.; Gibson, M.; Yang, S.; Forastiere, A.A.; Putnam, J.B. Primary Combined Modality Therapy for Esophageal Cancer. Oncology. 2006;20(5):505-511.
Montgomery, E.; Mamelak, A.J.; Gibson, M.; Maitra, A.; Sheikh, S.; Amr, S.S.; Yang, S.; Brock, M.; Forastiere, A.; Zhang, S.; Murphy, K.M.; Berg, K.D. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):24-30.
Pfister, D.G.; Laurie, S.A.; Weinstein, G.S.; Mendenhall, W.M.; Adelstein, D.J.; Ang, K.K.; Clayman, G.L.; Fisher, S.G.; Forastiere, A.A.; Harrison, L.B.; Lefebvre, J.L.; Leupold, N.; List, M.A.; O''Malley, B.O.; Patel, S.; Posner, M.R.; Schwartz, M.A.; Wolf, G.T. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006 Aug 1;24(22):3693-3704.
Cmelak, A.J.; Li, S.; Goldwasser, M.A.; Murphy, B.; Cannon, M.; Pinto, H.; Rosenthal, D.I.; Gillison, M.; Forastiere, A.A. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol. 2007 Sep 1;25(25):3971-3977.
Forastiere, A.A.; Burtness, B.A. Epidermal growth factor receptor inhibition in head and neck cancer-more insights, but more questions. J Clin Oncol. 2007 Jun 1;25(16):2152-2155.
Heath, E.I.; Canto, M.I.; Piantadosi, S.; Montgomery, E.; Weinstein, W.M.; Herman, J.G.; Dannenberg, A.J.; Yang, V.W.; Shar, A.O.; Hawk, E.; Forastiere, A.A. Secondary chemoprevention of Barrett''s esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007 Apr 4;99(7):545-557.
Jimeno, A.; Kulesza, P.; Wheelhouse, J.; Chan, A.; Zhang, X.; Kincaid, E.; Chen, R.; Clark, D.P.; Forastiere, A.; Hidalgo, M. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer. 2007 Mar 26;96(6):952-959.
Kleinberg, L.; Forastiere, A.A. Chemoradiation in the management of esophageal cancer. J Clin Oncol. 2007 Sep 10;25(26):4110-4117.
Kleinberg, L.; Gibson, M.K.; Forastiere, A.A. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nature clinical practice. 2007 May;4(5):282-294.
Poeta, M.L.; Manola, J.; Goldwasser, M.A.; Forastiere, A.; Benoit, N.; Califano, J.A.; Ridge, J.A.; Goodwin, J.; Kenady, D.; Saunders, J.; Westra, W.; Sidransky, D.; Koch, W.M. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007 Dec 20;357(25):2552-2561.
Trotti, A.; Pajak, T.F.; Gwede, C.K.; Paulus, R.; Cooper, J.; Forastiere, A.; Ridge, J.A.; Watkins-Bruner, D.; Garden, A.S.; Ang, K.K.; Curran, W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007 Jul;8(7):613-624.
Burtness, B.A.; Manola, J.; Axelrod, R.; Argiris, A.; Forastiere, A.A. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 May;19(5):977-983.
Cohen, E.E.; Rosen, L.S.; Vokes, E.E.; Kies, M.S.; Forastiere, A.A.; Worden, F.P.; Kane, M.A.; Sherman, E.; Kim, S.; Bycott, P.; Tortorici, M.; Shalinsky, D.R.; Liau, K.F.; Cohen, R.B. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-4713.
el-Shami, K.; Forastiere, A.A. Head and Neck Cancer. In: Ettinger, D., et al, editor. 5th Edition ed, Current Cancer Therapeutics. New York, NY: Churchill-Livingstone; 2008.
Fakhry, C.; Westra, W.H.; Li, S.; Cmelak, A.; Ridge, J.A.; Pinto, H.; Forastiere, A.; Gillison, M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008 Feb 20;100(4):261-269.
Forastiere, A.; Weber, R.; Ang, K. Treatment of head and neck cancer. N Engl J Med. 2008 Mar 6;358(10):1076; author reply 1077-1078.
Forastiere, A.A. Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol. 2008 Jun 15;97(8):701-707.
Forastiere, A.A.; Ang, K.K.; Brizel, D.; Brockstein, B.E.; Burtness, B.A.; Cmelak, A.J.; Colevas, A.D.; Dunphy, F.; Eisele, D.W.; Goepfert, H.; Hicks, W.L., Jr.; Kies, M.S.; Lydiatt, W.M.; Maghami, E.; Martins, R.; McCaffrey, T.; Mittal, B.B.; Pfister, D.G.; Pinto, H.A.; Posner, M.R.; Ridge, J.A.; Samant, S.; Schuller, D.E.; Shah, J.P.; Spencer, S.; Trotti, A., 3rd; Weber, R.S.; Wolf, G.T.; Worden, F. Head and neck cancers. J Natl Compr Canc Netw. 2008 Aug;6(7):646-695.
Garden, A.S.; Harris, J.; Trotti, A.; Jones, C.U.; Carrascosa, L.; Cheng, J.D.; Spencer, S.S.; Forastiere, A.; Weber, R.S.; Ang, K.K. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1351-1355.
Giantonio, B.J.; Forastiere, A.A.; Comis, R.L. The role of the Eastern Cooperative Oncology Group in establishing standards of cancer care: over 50 years of progress through clinical research. Semin Oncol. 2008 Oct;35(5):494-506.
Juergens, R.A.; Forastiere, A. Combined modality therapy of esophageal cancer. J Natl Compr Canc Netw. 2008 Oct;6(9):851-860; quiz 861.
Kleinberg, L.R.; Brock, M.V.; Jagannath, S.B.; Forastiere, A.A. Cancer of the Esophagus. In: Abeloff, M.e.a., editor. 4th Edition ed, Clinical Oncology. New York, NY: Churchill-Livingstone; 2008.
Machtay, M.; Moughan, J.; Trotti, A.; Garden, A.S.; Weber, R.S.; Cooper, J.S.; Forastiere, A.; Ang, K.K. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008 Jul 20;26(21):3582-3589.
Marur, S.; Forastiere, A.A. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008 Apr;83(4):489-501.
Sanguineti, G.; Forastiere, A.A. Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer. Nature clinical practice. 2008 Dec;5(12):694-695.
Shar, A.O.; Gaudard, M.A.; Heath, E.I.; Forastiere, A.A.; Yang, V.W.; Sontag, S.J. Quantitative endoscopy in the chemoprevention of Barrett''s Esophagus Trial. Dis Esophagus. 2008;21(7):641-644.
Yoon, H.H.; Forastiere, A.A. Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. Future oncology (London, England). 2008 Jun;4(3):413-425.
Adelstein, D.J.; Ridge, J.A.; Gillison, M.L.; Chaturvedi, A.K.; D''Souza, G.; Gravitt, P.E.; Westra, W.; Psyrri, A.; Kast, W.M.; Koutsky, L.A.; Giuliano, A.; Krosnick, S.; Trotti, A.; Schuller, D.E.; Forastiere, A.; Ullmann, C.D. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck. 2009 Nov;31(11):1393-1422.
Argiris, A.; Buchanan, A.; Brockstein, B.; Kolesar, J.; Ghebremichael, M.; Pins, M.; Hahn, K.; Axelrod, R.; Forastiere, A. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009 Oct 1;115(19):4504-4513.
Burtness, B.; Gibson, M.; Egleston, B.; Mehra, R.; Thomas, L.; Sipples, R.; Quintanilla, M.; Lacy, J.; Watkins, S.; Murren, J.R.; Forastiere, A.A. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol. 2009 Jul;20(7):1242-1248.
El-Naggar, A.K.; Kaye, F.J.; Shirazi, Y.; Gutkind, J.S.; Forastiere, A.A. Meeting report-the NIDCR 2(nd) Salivary Gland Tumor Meeting, November 2008. Head Neck. 2009 Dec;31(12):1542-1543.
Forastiere, A.A.; Marur, S. Head and Neck Cancer. In: Moore, A., editor. 4th Edition ed, ASCO Medical Oncology Self-Evaluation Program. Alexandria, VA: American Society of Clinical Oncology; 2009.
Forastiere, A.A.; Shaha, A.R. Chemotherapy alone for laryngeal preservation-is it possible? J Clin Oncol. 2009 Apr 20;27(12):1933-1934.
Forastiere, A.A.; Trotti, A.M. Searching for less toxic larynx preservation: a need for common definitions and metrics. J Natl Cancer Inst. 2009 Feb 4;101(3):129-131.
Higgins, M.J.; Forastiere, A.; Marur, S. New directions in the systemic treatment of metastatic thyroid cancer. Oncology. 2009;23(9):768-775.
Koch, W.M.; Ridge, J.A.; Forastiere, A.; Manola, J. Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614. Arch Otolaryngol Head Neck Surg. 2009 Sep;135(9):851-858.
Meguid, R.A.; Hooker, C.M.; Taylor, J.T.; Kleinberg, L.R.; Cattaneo, S.M., 2nd; Sussman, M.S.; Yang, S.C.; Heitmiller, R.F.; Forastiere, A.A.; Brock, M.V. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg. 2009 Dec;138(6):1309-1317.
Poeta, M.L.; Manola, J.; Goldenberg, D.; Forastiere, A.; Califano, J.A.; Ridge, J.A.; Goodwin, J.; Kenady, D.; Saunders, J.; Westra, W.; Sidransky, D.; Koch, W.M. The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins. Clin Cancer Res. 2009 Dec 15;15(24):7658-7665.
Rosenthal, D.I.; Harris, J.; Forastiere, A.A.; Weber, R.S.; Ridge, J.A.; Myers, J.N.; Garden, A.S.; Kuettel, M.R.; Sidhu, K.; Schultz, C.J.; Trotti, A.; Ang, K.K. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009 Oct 1;27(28):4727-4732.
Sanguineti, G.; Califano, J.; Stafford, E.; Fox, J.; Koch, W.; Tufano, R.; Sormani, M.P.; Forastiere, A. Defining the Risk of Involvement for Each Neck Nodal Level in Patients With Early T-Stage Node-Positive Oropharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2009 Jan 6.
Shar, A.O.; Gaudard, M.A.; Heath, E.I.; Forastiere, A.A.; Yang, V.W.; Sontag, S.J. Modeling using baseline characteristics in a small multicenter clinical trial for Barrett''s esophagus. Contemporary clinical trials. 2009 Jan;30(1):2-7.
Wee, J.T.; Anderson, B.O.; Corry, J.; D''Cruz, A.; Soo, K.C.; Qian, C.N.; Chua, D.T.; Hicks, R.J.; Goh, C.H.; Khoo, J.B.; Ong, S.C.; Forastiere, A.A.; Chan, A.T. Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009 Nov;10(11):1086-1092.
Altiok, S.; Mezzadra, H.; Jagannath, S.; Tsottles, N.; Rudek, M.A.; Abdallah, N.; Berman, D.; Forastiere, A.; Gibson, M.K. A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. Int J Oncol. 2010 Jan;36(1):19-27.
Chung, C.H.; Seeley, E.H.; Roder, H.; Grigorieva, J.; Tsypin, M.; Roder, J.; Burtness, B.A.; Argiris, A.; Forastiere, A.A.; Gilbert, J.; Murphy, B.; Caprioli, R.M.; Carbone, D.P.; Cohen, E.E. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-365.
Forastiere, A.A. Larynx preservation and survival trends: should there be concern? Head Neck. 2010 Jan;32(1):14-17.
Forastiere, A.A.; Marur, S. Head and Neck Cancer. Second Edition ed, ASCO-Sep: Medical Oncology Self-Evaluation Program; 2010.
Gourin, C.G.; Tufano, R.P.; Forastiere, A.A.; Koch, W.M.; Pawlik, T.M.; Bristow, R.E. Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1191-1198.
Konski, A.; Bhargavan, M.; Owen, J.; Paulus, R.; Cooper, J.; Forastiere, A.; Ang, K.K.; Watkins-Bruner, D. Feasibility of Economic Analysis of Radiation Therapy Oncology Group (RTOG) 91-11 using Medicare Data. Int J Radiat Oncol Biol Phys. 2010 May 14;79(2):436-442.
Marur, S.; D''Souza, G.; Westra, W.H.; Forastiere, A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010 Aug;11(8):781-789.
Marur, S.; Forastiere, A.A. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer. Curr Opin Oncol. 2010 May;22(3):206-211.
Quon, H.; Leong, T.; Haselow, R.; Leipzig, B.; Cooper, J.; Forastiere, A. Phase III Study of Radiation Therapy With or Without Cis-Platinum in Patients with Unresectable Squamous or Undifferentiated Carcinoma of the Head and Neck: An Intergroup Trial of the Eastern Cooperative Oncology Group (E2382). Int J Radiat Oncol Biol Phys. 2010 Sep 30;Epub ahead of print.
Is this you? Edit Profile
back to top button